Evidence map›Paper›PMID 29594214›Full record

ArticleClinical and translational radiation oncology2017

SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy.

Chiara De-Colle, David Mönnich, Stefan Welz, Simon Boeke, Bence Sipos, Falko Fend, Paul-Stefan Mauz, Inge Tinhofer, Volker Budach, Jehad Abu Jawad and 16 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Recent progress of biomarkers in oral cancers.Journal of the Chinese Medical Association : JCMA · 2021
    Article
  5. Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment.International journal of molecular sciences · 2021
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 1 country.

Chiara De-ColleRadiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
David MönnichRadiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
Stefan WelzRadiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
Simon BoekeRadiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
Bence SiposDepartment of Pathology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
Falko FendDepartment of Pathology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
Paul-Stefan MauzDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
Inge TinhoferGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Berlin, Germany.
Volker BudachGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Berlin, Germany.
Jehad Abu JawadGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Essen, Germany.
Martin StuschkeGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Essen, Germany.
Panagiotis BalermpasGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Frankfurt, Germany.
Claus RödelGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Frankfurt, Germany.
Anca-Ligia GrosuGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Freiburg, Germany.
Amir AbdollahiGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Heidelberg, Germany.
Jürgen DebusGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Heidelberg, Germany.
Christine BayerGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Munich, Germany.
Claus BelkaGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Munich, Germany.
Steffi PigorschGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Munich, Germany.
Stephanie E CombsGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Munich, Germany.
Fabian LohausGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Dresden, Germany.
Annett LingeGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Dresden, Germany.
Mechthild KrauseGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Dresden, Germany.
Michael BaumannGerman Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Dresden, Germany.
Daniel ZipsRadiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
Apostolos MenegakisRadiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
University of Tübingen · DEHeidelberg University · DEDeutschen Konsortium für Translationale Krebsforschung · DEGerman Cancer Research Center · DEUniversity of Duisburg-Essen · DEGoethe University Frankfurt · DEHelmholtz Zentrum München · DEOncoRay · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOutcome after postoperative radiochemotherapy (RT-CT) for patients with advanced head and neck squamous cell carcinomas (HNSCC) remains unsatisfactory, especially among those with HPV negative tumours. Therefore, new biomarkers are needed to further define subgroups for individualised therapeutic approaches. Preclinical and first clinical observations showed that the chemokine receptor CXCR4 and its ligand SDF-1 (CXCL12) play an important role in tumour cell proliferation, survival, cancer progression, metastasis and treatment resistance. However, the data on the prognostic value of SDF-1/CXCR4 expression for HNSCC are conflicting. The aim of our hypothesis-generating study was to retrospectively explore the prognostic potential of SDF-1/CXCR4 in a well-defined cohort of HNSCC patients collected within the multicenter biomarker study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). MATERIAL AND

methodsPatients with stage III and IVA HNSCC of the oral cavity, oropharynx and hypopharynx were treated with resection and adjuvant radiotherapy (RT) with ≥60 Gy and concurrent cisplatin-based chemotherapy (CT). Tissue micro-arrays (TMAs) from a total of 221 patients were generated from surgical specimens, 201 evaluated for the SDF-1 and CXCR4 expression by immunofluorescence and correlated with clinico-pathological and outcome data.

resultsIn univariate and multivariate analyses intracellular SDF-1 expression was associated with lower loco-regional control (LRC) in the entire patient group as well as in the HPV16 DNA negative subgroup. CXCR4 expression showed a trend for lower LRC in the univariate analysis which was not confirmed in the multivariate analysis. Neither for SDF-1 nor CXCR4 expression associations with distant metastasis free or overall survival were found.

conclusionsOur exploratory data support the hypothesis that overexpression of intracellular SDF-1 is an independent negative prognostic biomarker for LRC after postoperative RT-CT in high-risk HNSCC. Prospective validation is warranted and further exploration of SDF-1/CXCR4 as a potential therapeutic target to overcome treatment resistance in HNSCC appears promising.

Indexed as

BiomarkerCXCR4Head and neck cancerPostoperative radiochemotherapyPrognosticSDF-1

Identifiers

PMID29594214
PMCPMC5833920
OpenAlexW2735345375

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.